Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Breezula, a topical treatment, is anticipated to be available in the US by mid-2027 as a potential alternative to finasteride with fewer systemic side effects. There is ongoing debate about its effectiveness and some users report similar side effects to finasteride.

The conversation discusses the effectiveness of using 2.5 mg Dutasteride daily versus combining 0.5 mg Dutasteride with 150 mg RU58841 for reducing scalp DHT. Opinions vary, with some users recommending lower doses of Dutasteride and cautioning against RU58841 due to potential side effects.

Topical spironolactone is discussed as a hair loss treatment, with concerns about its effectiveness and side effects compared to finasteride and minoxidil. Users mention its unpleasant smell, potential systemic absorption, and suggest alternatives like pyrilutamide and alfatradiol.

A user taking dutasteride and minoxidil for hair loss is considering adding RU58841 to their regimen due to unsatisfactory results. Other users suggest alternatives and discuss the potential temporary benefits and limitations of RU58841.

The conversation discusses the ineffectiveness of dutasteride in halting hair loss for the user and explores the potential of PP405, which works through a different mechanism. Suggestions include considering a biopsy to determine the cause of hair loss and exploring other treatments like RU58841.

RU58841 5% is theoretically equivalent to 2mg of dutasteride for hair loss treatment, with RU58841 offering higher potential but more variability due to absorption issues. Users discuss the effectiveness of RU58841 and dutasteride, with some preferring dutasteride for consistent results and others finding success with RU58841.

A new hair loss protocol using FDA-approved topical treatments targets eight pathways, potentially improving results by 60-75% compared to the standard 40-50% from oral minoxidil and finasteride. The protocol includes minoxidil, finasteride, tacrolimus, cetirizine, bimatoprost, lithium gluconate, losartan, melatonin, NAC, caffeine, and tretinoin, with a monthly cost of $35-50 in Mexico and $80-150 in the US.

Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.

Creatine may counteract minoxidil's hair growth effects by closing potassium ATP channels, potentially leading to hair loss in predisposed individuals. Despite anecdotal reports, there is no conclusive evidence linking creatine to hair loss.

A 23-year-old has been using finasteride, dutasteride, and spironolactone to combat hair loss and hormonal acne, with mixed results and concerns about side effects. The user is experimenting with spironolactone despite its potential risks, hoping for skin and body hair improvements.

Promising hair loss treatments in clinical trials include Pyrilutamide, GT20029, CB-03-01, and PP405, with potential market releases between 2027 and 2029. Hair cloning remains experimental and expensive, while existing treatments like finasteride, minoxidil, and microneedling continue to be used.

The conversation humorously discusses diverting DHT from head to body hair and explores the idea of transplanting body hair to the scalp. It also mentions the potential for treatments to prevent DHT from affecting hair follicles.

PP405 is a new hair loss treatment showing early promise with a 20% hair density increase, but skepticism exists due to past failures of similar treatments like Pyrilutamide, RU58841, and Bimatoprost. Users debate its potential effectiveness, with some hopeful due to Google's involvement, while others urge caution without more evidence.

Hair loss treatments are advancing, with Coegin Pharma's FOL005 expected this year and Breezula potentially later. Pyrilutamide is available but not very effective, while Kintor's products face skepticism; traditional treatments like finasteride and minoxidil remain dominant.

Finasteride may decrease free testosterone by increasing SHBG, potentially causing side effects like reduced libido and hormonal changes. Some find it effective for hair loss, while others experience negative effects.

Cannabis and THC may have mixed effects on hair, with some studies suggesting potential negative impacts on hair growth in isolated hair follicles, but these results are hard to apply to living humans. Treatments like minoxidil and finasteride are commonly used for hair loss, and the effects of cannabis might be neutral or vary based on individual factors.

OP is using dermarolling, Minoxidil, rosemary oil, and keto shampoo for hair regrowth. Users suggest adding pyrilutamide or finasteride, but OP is cautious due to potential side effects.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

A user on dutasteride and oral minoxidil for two years has experienced worsening hair loss and an itchy scalp. Suggestions include increasing medication doses, trying other treatments like RU58841, getting a scalp biopsy, and addressing potential inflammation through diet and topical treatments.

Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.

Coffee may negatively impact hair health due to its vasoconstrictor effects, potential to increase DHT, and interference with nutrient absorption. There is no strong clinical evidence linking caffeine to hair loss or regrowth in humans, but moderation is advised.

Breezula protects hair follicles from both testosterone and DHT, unlike finasteride, which only protects against DHT. This could potentially lead to significant hair regrowth, similar to results seen in transgender individuals using hormone blockers.

Combining dutasteride and an aromatase inhibitor may increase testosterone levels significantly, potentially enhancing athletic performance but also posing health risks like elevated blood pressure and worsened cholesterol. The user is experimenting with dutasteride, anastrozole, minoxidil, and ketoconazole shampoo to manage hair loss and estradiol levels, while monitoring side effects and hormone levels.

RU58841 is discussed as a hair loss treatment, with concerns about potential heart risks and systemic side effects. Some users suggest trying FDA-approved treatments like finasteride first, while others debate the safety and cost-effectiveness of RU58841.

A 23-year-old user shared progress pictures after 12 months of using 1.25mg finasteride daily, reporting reduced hair shedding and considering adding 2.5mg oral minoxidil for further improvement. The discussion includes potential side effects of oral minoxidil, with users advising caution and monitoring under medical supervision.

Scalp Botox may help hair loss by relaxing muscles and increasing blood flow, potentially benefiting conditions other than androgenetic alopecia. DHT affects hair follicles differently, causing tension and hair loss in some areas but not others.

Young people are using hair loss treatments like finasteride and dutasteride without having hair loss, influenced by social media trends. Concerns are raised about the potential long-term effects of taking these medications at a young age.

The conversation discusses hair loss treatments, specifically the use of minoxidil and the potential addition of finasteride. The user has seen some progress with minoxidil but is hesitant about finasteride due to possible side effects, while others suggest combining both for better long-term results.

Topical sodium valproate may promote hair growth by inhibiting GSK3β, allowing beta-catenin to proliferate, but it has potential side effects and requires more research. The conversation also mentions skepticism about a product called Vdphlo1, which includes sodium valproate and other ingredients.

The conversation discusses using estradiol mesotherapy to replicate hormone replacement therapy results while minimizing systemic exposure. It also covers the use of Spironolactone cream, which reportedly has no systemic side effects, and the potential risks of using bicalutamide and Spironolactone in men.